Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Creates Life-Science Advisory Board

NEW YORK, Feb. 6 - Agilent Technologies has formed a life-sciences advisory board "to identify and evaluate technologies and applications" in the biotech sector, the company said Feb. 4.

 

"This is one more step toward accelerating our growth as a leading supplier of gene expression, proteomics and pharmaceutical analysis solutions," Chris Van Ingen, general manager of Agilent's life sciences and chemical analysis division, said in a statement.

 

Members of the board, which is expected to meet two or three times each year, include Paul Herring, director of corporate research at Novartis International; Anthony Martin, president and CEO of Molecular Probes.; Mark Skolnick, founder of Myriad Genetics; and, Wendell Wierenga, CEO of Syrrx.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.